Navigation Links
ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
Date:1/13/2009

PHILADELPHIA and LYON, France, Jan. 13 /PRNewswire-USNewswire/ -- ERYtech Pharma, French Biotechnology Company, and the Penn Jersey Region of American Red Cross are pleased to announce the signature of an agreement concerning the GMP clinical batches production of ERYtech Pharma's products in the United States.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/DC58023LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO)

ERYtech Pharma's co-founder and COO, Pierre-Olivier Goineau says, "this agreement allows ERYtech Pharma to be industrially present in the United States; it is an important step for the development of our products."

"This partnership enables the American Red Cross to show patients and donors that we are committed to providing the best services available," says Brigid O'Neill-LaGier, Chief Executive Officer of the American Red Cross Penn-Jersey Blood Services Region.

ERYtech Pharma's Co-Founder and CEO, Yann Godfrin concludes, "We are pleased to have reached this agreement and we think already to other projects of partnership with the American Red Cross for the development of our products."

About ERYtech Pharma

ERYtech Pharma is a leading biotechnology company developing next generation medicinal products making a huge positive impact on the lives of patients with serious unmet clinical needs.

A pioneer in the encapsulation of therapeutic molecules inside red blood cells, it is developing a pipeline of innovative therapeutics in orphan indications or underserved subpopulation of high risk patient's through its proprietary technology of entrapment and in-depth exploration of red cell physiologic properties.

ERYtech is focused in the fields of Haematology, Oncology and Metabolic Diseases. ERYtech Pharma's most advanced product, GRASPA(R), has completed a Phase II clinical trial in leukaemia and is currently being evaluated in the indication of several solid tumours. Beyond GRASPA(R), ERYtech has several investigational compounds addressing specific unmet clinical needs through enhanced efficacy, better compliance, reduced dosage or increased safety profile.


'/>"/>
SOURCE American Red Cross, Penn-Jersey Region; ERYtech Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... ALAMEDA, Calif. , Dec. 8, 2016  Singulex, ... Single Molecule Counting technology, entered into a license and ... in serving science. The agreement provides Singulex access to ... Europe is used to diagnose ... the United States to aid in assessing ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):